會員中心
新冠研究蛋白、抗體等試劑庫
發布時間：2022-06-15 16:16:45 點擊：1592
新冠研究蛋白、抗體等試劑庫
由新冠病毒引起的新冠肺炎疫情影響了全球的醫療衛生系統以及經濟，同時不斷突變的新毒株對新冠疫苗、治療藥物以及診斷都帶來了巨大的挑戰。義翹神州一直密切關注新冠病毒的進化情況，已保證第一時間研發出新冠病毒相關的蛋白、抗體等試劑。目前，我們的蛋白、抗體試劑以廣泛被全球科學家們用于新冠相關的各方面的研究，已助力正式發表900多篇科研論文。除此之外，我們的試劑產品也被用于免疫檢測試劑的核心原料用于其開發上市。我們已開發了擁有200+新冠突變體蛋白的突變體蛋白庫，覆蓋了VOC, VOI等突變位點。這些突變體蛋白也已經被研究著們用于新冠病毒免疫逃逸等相關研究。
重組新冠抗原
重組Spike蛋白
重組N蛋白
重組突變體蛋白庫
酶類，NSP蛋白等
宿主受體ACE2蛋白
SARS-CoV-2 Spike 蛋白推薦
| 貨號 | 抗原 | 表達宿主 | 標簽 |
| 40591-V08H | S1 | HEK293 Cells | His |
| 40590-V08B | S2 | Baculovirus-Insect Cells | His |
| 40592-V05H | RBD | HEK293 Cells | mFc |
| 40592-V08B | RBD | Baculovirus-Insect Cells | His |
| 40592-V08H | RBD | HEK293 Cells | His |
更多SARS-CoV-2 Spike 蛋白
| 貨號 | 抗原 | 表達宿主 | 標簽 |
| 40589-V08H4 | S1+S2 ECD | HEK293 Cells | His |
| 40591-V02H | S1 | HEK293 Cells | Fc |
| 40591-V05H1 | S1 | HEK293 Cells | mFc |
| 40591-V08B1 | S1 | Baculovirus-Insect Cells | His |
| 40591-V08H-B Biotinylated | S1 | HEK293 Cells | His |
| 40591-V27H-B Biotinylated | S1 | HEK293 Cells | AVI & His |
| 40591-V41H | S1 NTD | HEK293 Cells | Fc & AVI |
| 40591-V41H-B Biotinylated | S1 NTD | HEK293 Cells | Fc & AVI |
| 40591-V49H | S1 NTD | HEK293 Cells | His & AVI |
| 40591-V49H-B Biotinylated | S1 NTD | HEK293 Cells | His & AVI |
| 40589-V08B1 | S1+S2 ECD | Baculovirus-Insect Cells | His |
| 40589-V08B1-B Biotinylated | S1+S2 ECD | Baculovirus-Insect Cells | His |
| 40589-V27B-B Biotinylated | S1+S2 ECD | Baculovirus-Insect Cells | AVI & His |
| 40590-V02H | S2 | HEK293 Cells | Fc |
| 40590-V05B | S2 | Baculovirus-Insect Cells | mFc |
| 40590-V08B-B Biotinylated | S2 | Baculovirus-Insect Cells | His |
| 40590-V08H1 | S2 | HEK293 Cells | His |
| 40592-V02H | RBD | HEK293 Cells | Fc |
| 40592-V08B-B Biotinylated | RBD | Baculovirus-Insect Cells | His |
| 40592-V08H-B Biotinylated | RBD | HEK293 Cells | His |
| 40592-V27B-B Biotinylated | RBD | Baculovirus-Insect Cells | AVI & His |
| 40592-V27H-B Biotinylated | RBD | HEK293 Cells | AVI & His |
| 40592-V31H | RBD | HEK293 Cells | rFc |
| 40592-VNAH | RBD | HEK293 Cells |
新冠抗體試劑
義翹神州開發生產了針對新冠病毒不同抗原抗體試劑，特異性、中和效應以及多種應用均經過驗證。
高親和力
Binding affinity has been validated by BLI assay.
BLI: KD=0.006 nM
Anti-Spike Rabbit MAb (cat#:40592-R001)
BLI: KD=0.01 nM
Anti-N Rabbit MAb (cat#:40143-R040)
高特異性
ELISA assay has been taken to validate the cross-reactivity with Spike antigens from different Human Coronaviruses.
No cross-reactivity with SARS-CoV, MERS-CoV, HKU1, 229E, NL63, and OC43.
中和效應
The anti-RBD neutralizing antibody could effectively block the binding between recombinant spike RBD and ACE2 protein, and inhibit the infection of spike pseudovirus to ACE2 overexpressed HEK293T cells.
Anti-Spike RBD Mouse MAb (cat#: 40592-MM57)
 |  |  |
試劑盒采用雙抗夾心ELISA法，可以快速定量檢測N蛋白和S蛋白。試劑盒中使用的抗體均為義翹神州自主研發生產的單克隆抗體，已實現大量生產且可保證批次間穩定性。其中，S試劑盒經過重組蛋白和假病毒檢測雙重驗證。 | SARS-CoV-2 N Detection Kit (KIT40588)  | |
| 更多詳情：新冠病毒抗原蛋白檢測試劑盒 | ||
| ? 新冠病毒抑制劑篩選試劑盒 ? 新冠病毒抗體滴度檢測試劑盒 | ||
新冠試劑發表文獻
截止到4月30日，已有近500篇正式發表的文章以及120篇預發表文章引用了義翹神州開發的新冠相關科研試劑。
| 題目 | 期刊 | 作者 | 年份 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity | Cell | Thomson, E,et al. | 2021 |
| Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection | Cell | Brouwer, PJM,et al. | 2021 |
| The antigenic anatomy of SARS-CoV-2 receptor binding domain | Cell | Dejnirattisai, W,et al. | 2021 |
| BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection | Cell | Mills, R,et al. | 2021 |
| COVID-19 immune features revealed by a large-scale single cell transcriptome atlas | Cell | Ren, X,et al. | 2021 |
| Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia | Cell | Asarnow, D,et al. | 2021 |
| Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\' B cells | Cell | Cao, Y,et al. | 2020 |
| Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies | Cell | Wrapp, Daniel,et al. | 2020 |
| Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment | Cell | Sun, J,et al. | 2020 |
| Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 | Cell | Wang, H,et al. | 2020 |
| A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS | Cell | Dai, L,et al. | 2020 |
| The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity | Cell | Li, Q,et al. | 2020 |
| A thermostable mRNA vaccine against COVID-19 | Cell | Zhang, N,et al. | 2020 |
| High potency of a bivalent human VH domain in SARS-CoV-2 animal models | Cell | Li, W,et al. | 2020 |
| Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology | Cell | Piccoli, L,et al. | 2020 |
| Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant | Cell | Yurkovetskiy, L,et al. | 2020 |
| Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy | Cell | Du, S,et al. | 2020 |
| Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19 | Cell | Meckiff, B,et al. | 2020 |
| Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production | Cell | Chen, Y,et al. | 2020 |
| Compromised humoral functional evolution tracks with SARS-CoV-2 mortality | Cell | Zohar, T,et al. | 2020 |
| A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 | Cell | Hassan, AO,et al. | 2020 |
| Compromised SARS-CoV-2-specific placental antibody transfer | Cell | Atyeo, C,et al. | 2020 |
2019新型冠狀病毒，即"SARS-CoV-2 (2019-nCoV)"，因2019年武漢病毒性肺炎病例而被發現，和2003年的 SARS冠狀病毒以及2012年的MERS冠狀病毒同屬于冠狀病毒科β屬。
冠狀病毒基因組依次編碼棘突蛋白(spike protein)、包膜蛋白(Envelope protein)、膜蛋白(Membrane protein)和核衣殼蛋白(Nucleocapsid)。
棘突蛋白(spike protein) 是冠狀病毒最重要的表面膜蛋白，含有兩個亞基（subunit）， S1和S2。其中S1主要包含有受體結合區（receptorbinding domain， RBD），負責識別細胞的受體。S2含有膜融合過程所需的基本元件。
Spike 蛋白承擔病毒與宿主細胞膜受體結合及膜融合功能，是宿主中和抗體的重要作用位點以及疫苗設計的關鍵靶點。SARS-CoV-2 (2019-nCoV) 的Spike蛋白與人ACE2互作來感染人的呼吸道上皮細胞。
核衣殼蛋白是冠狀病毒中含量最豐富的蛋白。在病毒體組裝過程中，N蛋白與病毒RNA結合并導致螺旋核衣殼的形成。核衣殼蛋白是一種高度免疫原性的磷蛋白，與病毒基因組復制和調節細胞信號通路有關。由于N蛋白的序列保守性和強大的免疫原性，N蛋白常被作為冠狀病毒診斷檢測工具
義翹神州于1月22日全球首發新冠病毒（SARS-CoV-2）重要靶點Spike RBD重組蛋白。為了更好的支持新冠肺炎的研究，義翹神州開發生產了數百種新冠病毒（SARS-CoV-2）相關科研試劑，包括抗原蛋白（N蛋白、Spike全長胞外域、 Spike S1、Spike S2、Spike RBD, Plpro, MTase, NSP3, NSP8，NSP9）、單抗、抗原蛋白檢測試劑盒、抑制劑篩選試劑盒、抗體滴度檢測試劑盒以及即用型表達基因。這些科研試劑已被全球數百家研究機構用于疫苗和治療性抗體開發。義翹神州還可以提供新冠假病毒中和檢測服務，可用于篩選出具有中和活性的抗體或血清，支持藥物研發在細胞水平上的評估。
SARS-CoV-2 (2019-nCoV)抗原試劑產品列表
引用文獻
? Xintian Xu.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.SCIENCE CHINA Life Sciences.2020
? Bo Diao, Zeqing Feng.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv preprint
